GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AVEO Pharmaceuticals Inc (NAS:AVEO) » Definitions » Shiller PE Ratio

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Shiller PE Ratio : (As of May. 04, 2024)


View and export this data going back to 2010. Start your Free Trial

What is AVEO Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AVEO Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for AVEO Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVEO Pharmaceuticals Shiller PE Ratio Chart

AVEO Pharmaceuticals Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

AVEO Pharmaceuticals Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of AVEO Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, AVEO Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AVEO Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AVEO Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where AVEO Pharmaceuticals's Shiller PE Ratio falls into.



AVEO Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

AVEO Pharmaceuticals's E10 for the quarter that ended in Sep. 2022 is calculated as:

For example, AVEO Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2022 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2022 (Change)*Current CPI (Sep. 2022)
=-0.09/125.2265*125.2265
=-0.090

Current CPI (Sep. 2022) = 125.2265.

AVEO Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201212 -4.900 96.871 -6.334
201303 -6.900 98.209 -8.798
201306 -6.200 98.518 -7.881
201309 -4.700 98.790 -5.958
201312 -3.200 98.326 -4.075
201403 -1.200 99.695 -1.507
201406 -3.500 100.560 -4.359
201409 -2.800 100.428 -3.491
201412 -2.700 99.070 -3.413
201503 -2.100 99.621 -2.640
201506 -1.000 100.684 -1.244
201509 1.400 100.392 1.746
201512 -1.200 99.792 -1.506
201603 -1.300 100.470 -1.620
201606 -1.300 101.688 -1.601
201609 -0.700 101.861 -0.861
201612 -0.700 101.863 -0.861
201703 -1.200 102.862 -1.461
201706 -3.000 103.349 -3.635
201709 -2.200 104.136 -2.646
201712 -0.800 104.011 -0.963
201803 -0.800 105.290 -0.951
201806 -0.600 106.317 -0.707
201809 -1.800 106.507 -2.116
201812 -0.300 105.998 -0.354
201903 -0.620 107.251 -0.724
201906 -0.200 108.070 -0.232
201909 1.020 108.329 1.179
201912 -0.280 108.420 -0.323
202003 -0.520 108.902 -0.598
202006 -0.420 108.767 -0.484
202009 -0.330 109.815 -0.376
202012 -0.440 109.897 -0.501
202103 -0.810 111.754 -0.908
202106 -0.400 114.631 -0.437
202109 -0.300 115.734 -0.325
202112 -0.210 117.630 -0.224
202203 -0.300 121.301 -0.310
202206 -0.240 125.017 -0.240
202209 -0.090 125.227 -0.090

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AVEO Pharmaceuticals  (NAS:AVEO) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


AVEO Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of AVEO Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AVEO Pharmaceuticals (AVEO Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30 Winter Street, Boston, MA, USA, 02108
AVEO Pharmaceuticals Inc is a commercial-stage, oncology-focused biopharmaceutical company engaged in offering medicines that provide a better life for patients with cancer. The company markets FOTIVDA (tivozanib) in the United States. FOTIVDA is an oral, next-generation vascular endothelial growth factor receptor, or VEGFR, tyrosine kinase inhibitor, or TKI. The group primarily operates in the U.S.
Executives
Jebediah Ledell officer: Chief Operating Officer C/O AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Michael P Bailey director, officer: President & CEO IMCLONE SYSTEMS INCORPORATED, 180 VARICK STREET, 6TH FLOOR, NEW YORK NY 10014
Michael Ferraresso officer: Chief Commercial Officer AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Kevin Joseph Cullen director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Epperly Corinne director AVEO PHARMACEUTICALS, INC., 30 WINTER STREET, BOSTON MA 02108
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Scott D Sandell 10 percent owner
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Erick Lucera officer: Chief Financial Officer 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Scarlett Spring director AVEO PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Peter J Barris 10 percent owner 1119 ST PAUL STREET, BALTIMORE MD 21202

AVEO Pharmaceuticals (AVEO Pharmaceuticals) Headlines

From GuruFocus

LG Chem to Acquire AVEO Oncology for $15.00 Per Share in Cash

By Value_Insider Value_Insider 10-18-2022